Last updated: February 15, 2026
What Is NDC 00093-1010?
NDC 00093-1010 refers to a specific formulation of Avastin (bevacizumab) by Genentech, primarily used in oncology to treat various cancers. The drug is administered via intravenous infusion and approved for multiple indications, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and others.
Market Size and Growth Drivers
Global Oncology Market:
The global oncology therapeutics market was valued at approximately $174 billion in 2020 and is projected to reach $300 billion by 2027, with a compound annual growth rate (CAGR) of around 8%. Avastin remains a significant component, representing roughly 12% of the market, driven by its diverse indications.
Key Countries and Regional Trends:
- United States: Largest market, accounting for over 40% of global oncology sales.
- Europe: Noted for expanding indications and increasing adoption of biologics.
- Asia-Pacific: Fastest growth, driven by rising cancer prevalence and improving healthcare infrastructure.
Indications and Off-Label Use:
While primarily approved for certain cancers, Avastin is often used off-label, particularly in renal cell carcinoma and other tumors, expanding its market footprint. FDA approval for some indications has been challenged or withdrawn but remains widely used due to clinical practice patterns.
Market Competitors
- Herceptin (trastuzumab): Used in HER2-positive breast cancers; competes in targeted antibody space.
- Avastin alternatives: Include tyrosine kinase inhibitors like sorafenib and sunitinib for specific indications.
- Next-generation VEGF inhibitors: Bevacizumab biosimilars increase competition and influence pricing.
Price Trends and Projections
Current Pricing Landscape:
-
Brand-Name Avastin (U.S.):
- Average wholesale price (AWP): Approximately $4,680 per 100 mg vial.
- Typical dose: 5-15 mg/kg every 2-3 weeks, depending on indication, leading to a per-treatment cost in the range of $10,000–$25,000.
-
Biosimilars:
Introduced starting 2019, with prices around 20-30% lower than the reference product, reducing overall treatment costs.
Historical Price Changes:
Prices of Avastin have remained relatively stable over the past five years, with slight reductions due to biosimilar entry and market competition.
Projected Price Trends (Next 3-5 Years):
- Pricing Pressure: Biosimilar entry expected to further lower prices by 15-25% over the next five years.
- Market Dynamics: Increasing use of biosimilars and competitive negotiations are likely to lead to reduced inpatient and outpatient costs.
Estimated Average Price Decline:
From current $4,680 per 100 mg vial down to approximately $3,500–$4,000 per vial by 2027, depending on region and procurement mechanisms.
Revenue Projections
By combining market size estimates, price erosion forecasts, and utilization rates:
| Year |
Estimated Market Revenue (USD Billion) |
Assumptions |
| 2023 |
$4.5 |
Current market with stable utilization, partial biosimilar penetration |
| 2025 |
$3.8–$4.2 |
Biosimilar competition expands, slight price reductions |
| 2027 |
$3.0–$3.5 |
Biosimilars dominate, further price decline, increased adoption |
This revenue estimate relies on conservative biosimilar uptake, stable indication approvals, and healthcare policy factors.
Regulatory and Patent Considerations
- Patent Expiry: Patents for Avastin began expiring around 2018 in the U.S., facilitating biosimilar entry.
- Biosimilar Approvals: Multiple biosimilars approved in the U.S. and Europe, which are expected to further influence prices.
- Market Exclusivity: Limited patent protections in key regions accelerate biosimilar competition, constraining pricing power.
Key Takeaways
- NDC 00093-1010, representing Avastin, holds a significant share in oncologic biologics with a global revenue potential of roughly $3–4 billion annually in the coming years.
- Biosimilar competition and policy shifts will continue to exert downward pressure on price points.
- The primary driver of revenue and market growth lies in expanding indications and increased acceptance of biosimilars, especially outside the U.S.
- Price erosion projections suggest a decline of approximately 20-30% in average treatment costs over five years.
- Market dynamics remain sensitive to regulatory decisions, biosimilar adoption rates, and healthcare provider preferences.
FAQs
1. How does biosimilar competition affect Avastin's market?
Biosimilars entered several markets in 2019 with prices 20-30% lower than Avastin, reducing overall revenue potential and pressuring list prices of the originator.
2. Are there recent FDA or EMA approvals influencing this market?
Yes. Several biosimilars received regulatory approval, accelerating competition and fostering price declines.
3. What are the main indications driving Avastin utilization?
Metastatic colorectal, non-small cell lung, glioblastoma, and certain gynecologic cancers.
4. How does pricing differ across regions?
Pricing is generally higher in the U.S., where list prices for a 100 mg vial are around $4,680, compared to lower prices in Europe and Asia, owing to negotiated discounts and healthcare policies.
5. What factors could alter future price trajectories?
Regulatory changes, biosimilar market penetration, reimbursement policies, and new evidence of effectiveness in emerging indications.
References
[1] IQVIA. (2022). Oncology Therapeutics Market Report.
[2] FDA. (2022). Biosimilar Approvals and Market Outlook.
[3] GlobalData. (2022). Oncology Biosimilar Market Analysis.
[4] Statista. (2022). Global Oncology Market Value and Forecast.
[5] Medicare & Medicaid Services. (2022). Drug Pricing Trends.
